ID   EYA1_HUMAN              Reviewed;         592 AA.
AC   Q99502; A6NHQ0; G5E9R4; Q0P516; Q8WX80;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   15-MAR-2017, entry version 152.
DE   RecName: Full=Eyes absent homolog 1;
DE            EC=3.1.3.16 {ECO:0000269|PubMed:19234442};
DE            EC=3.1.3.48 {ECO:0000269|PubMed:19234442};
GN   Name=EYA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND VARIANTS BOR1
RP   PRO-487 AND ARG-505.
RC   TISSUE=Embryo;
RX   PubMed=9361030; DOI=10.1093/hmg/6.13.2247;
RA   Abdelhak S., Kalatzis V., Heilig R., Compain S., Samson D.,
RA   Vincent C., Levi-Acobas F., Cruaud C., le Merrer M., Mathieu M.,
RA   Koenig R., Vigneron J., Weissenbach J., Petit C., Weil D.;
RT   "Clustering of mutations responsible for branchio-oto-renal (BOR)
RT   syndrome in the eyes absent homologous region (eyaHR) of EYA1.";
RL   Hum. Mol. Genet. 6:2247-2255(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM EYA1A).
RC   TISSUE=Embryo;
RX   PubMed=9020840; DOI=10.1038/ng0297-157;
RA   Abdelhak S., Kalatzis V., Heilig R., Compain S., Samson D.,
RA   Vincent C., Weil D., Cruaud C., Sahly I., Leibovici M.,
RA   Bitner-Glindzicz M., Francis M., Lacombe D., Vigneron J.,
RA   Charachon R., Boven K., Bedbeder P., van Regemorter N.,
RA   Weissenbach J., Petit C.;
RT   "A human homologue of the Drosophila eyes absent gene underlies
RT   branchio-oto-renal (BOR) syndrome and identifies a novel gene
RT   family.";
RL   Nat. Genet. 15:157-164(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EYA1D), AND ALTERNATIVE SPLICING.
RC   TISSUE=Kidney;
RA   Vervoort V.S., Schwartz C.E.;
RT   "EYA1D, a novel EYA1 isoform.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INVOLVEMENT IN BOS1.
RX   PubMed=9359046;
RA   Vincent C., Kalatzis V., Abdelhak S., Chaib H., Compain S., Helias J.,
RA   Vaneecloo F.M., Petit C.;
RT   "BOR and BO syndromes are allelic defects of EYA1.";
RL   Eur. J. Hum. Genet. 5:242-246(1997).
RN   [8]
RP   INVOLVEMENT IN OTFCS1.
RX   PubMed=11409867; DOI=10.1007/s004390100495;
RA   Rickard S., Parker M., van't Hoff W., Barnicoat A., Russell-Eggitt I.,
RA   Winter R.M., Bitner-Glindzicz M.;
RT   "Oto-facio-cervical (OFC) syndrome is a contiguous gene deletion
RT   syndrome involving EYA1: molecular analysis confirms allelism with BOR
RT   syndrome and further narrows the Duane syndrome critical region to 1
RT   cM.";
RL   Hum. Genet. 108:398-403(2001).
RN   [9]
RP   SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=12500905; DOI=10.1023/A:1020990825644;
RA   Fougerousse F., Durand M., Lopez S., Suel L., Demignon J.,
RA   Thornton C., Ozaki H., Kawakami K., Barbet P., Beckmann J.S.,
RA   Maire P.;
RT   "Six and Eya expression during human somitogenesis and MyoD gene
RT   family activation.";
RL   J. Muscle Res. Cell Motil. 23:255-264(2002).
RN   [10]
RP   INVOLVEMENT IN OTFCS1.
RX   PubMed=16441263; DOI=10.1111/j.1529-8817.2005.00204.x;
RA   Estefania E., Ramirez-Camacho R., Gomar M., Trinidad A., Arellano B.,
RA   Garcia-Berrocal J.R., Verdaguer J.M., Vilches C.;
RT   "Point mutation of an EYA1-gene splice site in a patient with oto-
RT   facio-cervical syndrome.";
RL   Ann. Hum. Genet. 70:140-144(2006).
RN   [11]
RP   INVOLVEMENT IN BOS1.
RX   PubMed=16691597; DOI=10.1002/ajmg.a.31285;
RA   Spruijt L., Hoefsloot L.H., van Schaijk G.H.W.H., van Waardenburg D.,
RA   Kremer B., Brackel H.J.L., de Die-Smulders C.E.M.;
RT   "Identification of a novel EYA1 mutation presenting in a newborn with
RT   laryngomalacia, glossoptosis, retrognathia, and pectus excavatum.";
RL   Am. J. Med. Genet. A 140:1343-1345(2006).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-328.
RX   PubMed=19234442; DOI=10.1038/nature07849;
RA   Cook P.J., Ju B.G., Telese F., Wang X., Glass C.K., Rosenfeld M.G.;
RT   "Tyrosine dephosphorylation of H2AX modulates apoptosis and survival
RT   decisions.";
RL   Nature 458:591-596(2009).
RN   [13]
RP   VARIANT BOR1 GLN-440.
RX   PubMed=10464653; DOI=10.1089/gte.1997.1.243;
RA   Kumar S., Deffenbacher K., Cremers C.W.R.J., Van Camp G.,
RA   Kimberling W.J.;
RT   "Branchio-oto-renal syndrome: identification of novel mutations,
RT   molecular characterization, mutation distribution, and prospects for
RT   genetic testing.";
RL   Genet. Test. 1:243-251(1997).
RN   [14]
RP   VARIANTS ASA LYS-363 AND GLY-547, AND VARIANT BOR1 SER-426.
RX   PubMed=10655545; DOI=10.1093/hmg/9.3.363;
RA   Azuma N., Hirakiyama A., Inoue T., Asaka A., Yamada M.;
RT   "Mutations of a human homologue of the Drosophila eyes absent gene
RT   (EYA1) detected in patients with congenital cataracts and ocular
RT   anterior segment anomalies.";
RL   Hum. Mol. Genet. 9:363-366(2000).
RN   [15]
RP   VARIANT BOR1 PRO-583.
RX   PubMed=10991693; DOI=10.1136/jmg.37.8.623;
RA   Rickard S., Boxer M., Trompeter R., Bitner-Glindzicz M.;
RT   "Importance of clinical evaluation and molecular testing in the
RT   branchio-oto-renal (BOR) syndrome and overlapping phenotypes.";
RL   J. Med. Genet. 37:623-627(2000).
RN   [16]
RP   VARIANT BOR1 GLY-429.
RX   PubMed=11558900; DOI=10.1007/s100380170033;
RA   Namba A., Abe S., Shinkawa H., Kimberling W.J., Usami S.;
RT   "Genetic features of hearing loss associated with ear anomalies: PDS
RT   and EYA1 mutation analysis.";
RL   J. Hum. Genet. 46:518-521(2001).
RN   [17]
RP   VARIANT BOS1 GLY-242.
RX   PubMed=12701758; DOI=10.1080/0036554021000028103;
RA   Yashima T., Noguchi Y., Ishikawa K., Mizusawa H., Kitamura K.;
RT   "Mutation of the EYA1 gene in patients with branchio-oto syndrome.";
RL   Acta Oto-Laryngol. 123:279-282(2003).
RN   [18]
RP   VARIANTS BOR1 SER-95; SER-140; VAL-363; GLN-440; PRO-514; CYS-527 AND
RP   THR-569.
RX   PubMed=21280147; DOI=10.1002/humu.21402;
RA   Krug P., Moriniere V., Marlin S., Koubi V., Gabriel H.D., Colin E.,
RA   Bonneau D., Salomon R., Antignac C., Heidet L.;
RT   "Mutation screening of the EYA1, SIX1, and SIX5 genes in a large
RT   cohort of patients harboring branchio-oto-renal syndrome calls into
RT   question the pathogenic role of SIX5 mutations.";
RL   Hum. Mutat. 32:183-190(2011).
RN   [19]
RP   VARIANT LYS-41.
RX   PubMed=23508780; DOI=10.1007/s00439-013-1289-0;
RA   Reis L.M., Tyler R.C., Muheisen S., Raggio V., Salviati L., Han D.P.,
RA   Costakos D., Yonath H., Hall S., Power P., Semina E.V.;
RT   "Whole exome sequencing in dominant cataract identifies a new
RT   causative factor, CRYBA2, and a variety of novel alleles in known
RT   genes.";
RL   Hum. Genet. 132:761-770(2013).
CC   -!- FUNCTION: Functions both as protein phosphatase and as
CC       transcriptional coactivator for SIX1, and probably also for SIX2,
CC       SIX4 and SIX5 (By similarity). Tyrosine phosphatase that
CC       dephosphorylates 'Tyr-142' of histone H2AX (H2AXY142ph) and
CC       promotes efficient DNA repair via the recruitment of DNA repair
CC       complexes containing MDC1. 'Tyr-142' phosphorylation of histone
CC       H2AX plays a central role in DNA repair and acts as a mark that
CC       distinguishes between apoptotic and repair responses to genotoxic
CC       stress (PubMed:19234442). Its function as histone phosphatase may
CC       contribute to its function in transcription regulation during
CC       organogenesis (By similarity). Has also phosphatase activity with
CC       proteins phosphorylated on Ser and Thr residues (in vitro) (By
CC       similarity). Required for normal embryonic development of the
CC       craniofacial and trunk skeleton, kidneys and ears (By similarity).
CC       Together with SIX1, it plays an important role in hypaxial muscle
CC       development; in this it is functionally redundant with EYA2 (By
CC       similarity). {ECO:0000250|UniProtKB:P97767,
CC       ECO:0000269|PubMed:19234442}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000269|PubMed:19234442}.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC       {ECO:0000269|PubMed:19234442}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:O00167};
CC       Note=Binds 1 Mg(2+) ion per subunit.
CC       {ECO:0000250|UniProtKB:O00167};
CC   -!- SUBUNIT: Probably interacts with SIX2, SIX4 and SIX5. Interacts
CC       with H2AX in response to DNA damage. Interacts with SIX3; promotes
CC       EYA1 translocation to the nucleus. {ECO:0000250|UniProtKB:P97767}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12500905}.
CC       Nucleus {ECO:0000269|PubMed:12500905,
CC       ECO:0000269|PubMed:19234442}. Note=Localizes at sites of DNA
CC       damage at double-strand breaks (DSBs).
CC       {ECO:0000269|PubMed:19234442}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=EYA1A;
CC         IsoId=Q99502-1; Sequence=Displayed;
CC       Name=EYA1B;
CC         IsoId=Q99502-2; Sequence=VSP_001486;
CC       Name=EYA1D;
CC         IsoId=Q99502-3; Sequence=VSP_045793, VSP_045794;
CC   -!- TISSUE SPECIFICITY: In the embryo, highly expressed in kidney with
CC       lower levels in brain. Weakly expressed in lung. In the adult,
CC       highly expressed in heart and skeletal muscle. Weakly expressed in
CC       brain and liver. No expression in eye or kidney.
CC   -!- DEVELOPMENTAL STAGE: Detected in cytoplasm of somite cells at the
CC       beginning of fourth week of development. Detected in cytoplasm of
CC       limb bud cell between the sixth and eighth week of development.
CC       {ECO:0000269|PubMed:12500905}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250}.
CC   -!- DISEASE: Branchiootorenal syndrome 1 (BOR1) [MIM:113650]: A
CC       syndrome characterized by branchial cleft fistulas or cysts,
CC       sensorineural and/or conductive hearing loss, pre-auricular pits,
CC       structural defects of the outer, middle or inner ear, and renal
CC       malformations. {ECO:0000269|PubMed:10464653,
CC       ECO:0000269|PubMed:10655545, ECO:0000269|PubMed:10991693,
CC       ECO:0000269|PubMed:11558900, ECO:0000269|PubMed:21280147,
CC       ECO:0000269|PubMed:9361030}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Otofaciocervical syndrome 1 (OTFCS1) [MIM:166780]: A
CC       disorder characterized by facial dysmorphism, cup-shaped low-set
CC       ears, preauricular fistulas, hearing loss, branchial defects,
CC       skeletal anomalies including vertebral defects, low-set clavicles,
CC       winged scapulae, sloping shoulders, and mild intellectual
CC       disability. {ECO:0000269|PubMed:11409867,
CC       ECO:0000269|PubMed:16441263}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Branchiootic syndrome 1 (BOS1) [MIM:602588]: A syndrome
CC       characterized by usually bilateral branchial cleft fistulas or
CC       cysts, sensorineural and/or conductive hearing loss, pre-auricular
CC       pits, and structural defects of the outer, middle or inner ear.
CC       Otic defects include malformed and hypoplastic pinnae, a narrowed
CC       external ear canal, bulbous internal auditory canal, stapes
CC       fixation, malformed and hypoplastic cochlea. Branchial and otic
CC       anomalies overlap with those seen in individuals with the
CC       branchiootorenal syndrome. However renal anomalies are absent in
CC       branchiootic syndrome patients. {ECO:0000269|PubMed:12701758,
CC       ECO:0000269|PubMed:16691597, ECO:0000269|PubMed:9359046}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Anterior segment anomalies with or without cataract (ASA)
CC       [MIM:602588]: A disease characterized by various types of
CC       developmental eye anomalies, in the absence of other
CC       abnormalities. The phenotypic spectrum of anterior segment
CC       anomalies include central corneal opacity, Peters anomaly, and
CC       bilateral persistence of the pupillary membrane. Some patients
CC       have cataract. {ECO:0000269|PubMed:10655545}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the HAD-like hydrolase superfamily. EYA
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y10260; CAA71309.1; -; Genomic_DNA.
DR   EMBL; AJ000097; CAA03922.1; -; mRNA.
DR   EMBL; AJ000098; CAA03923.1; -; mRNA.
DR   EMBL; AF467247; AAL73437.1; -; mRNA.
DR   EMBL; AC016465; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022858; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471068; EAW86976.1; -; Genomic_DNA.
DR   EMBL; BC121799; AAI21800.1; -; mRNA.
DR   CCDS; CCDS34906.1; -. [Q99502-1]
DR   CCDS; CCDS34907.1; -. [Q99502-3]
DR   CCDS; CCDS47873.1; -. [Q99502-2]
DR   RefSeq; NP_000494.2; NM_000503.5. [Q99502-1]
DR   RefSeq; NP_001275503.1; NM_001288574.1.
DR   RefSeq; NP_001275504.1; NM_001288575.1.
DR   RefSeq; NP_742055.1; NM_172058.3. [Q99502-1]
DR   RefSeq; NP_742056.1; NM_172059.3. [Q99502-3]
DR   RefSeq; NP_742057.1; NM_172060.3. [Q99502-2]
DR   RefSeq; XP_016868695.1; XM_017013206.1. [Q99502-1]
DR   RefSeq; XP_016868701.1; XM_017013212.1. [Q99502-2]
DR   UniGene; Hs.444971; -.
DR   UniGene; Hs.491997; -.
DR   ProteinModelPortal; Q99502; -.
DR   SMR; Q99502; -.
DR   BioGrid; 108439; 8.
DR   DIP; DIP-60446N; -.
DR   IntAct; Q99502; 1.
DR   STRING; 9606.ENSP00000342626; -.
DR   DEPOD; Q99502; -.
DR   iPTMnet; Q99502; -.
DR   PhosphoSitePlus; Q99502; -.
DR   DMDM; 3183005; -.
DR   MaxQB; Q99502; -.
DR   PaxDb; Q99502; -.
DR   PeptideAtlas; Q99502; -.
DR   PRIDE; Q99502; -.
DR   Ensembl; ENST00000340726; ENSP00000342626; ENSG00000104313. [Q99502-1]
DR   Ensembl; ENST00000388740; ENSP00000373392; ENSG00000104313. [Q99502-2]
DR   Ensembl; ENST00000388742; ENSP00000373394; ENSG00000104313. [Q99502-1]
DR   Ensembl; ENST00000419131; ENSP00000410176; ENSG00000104313. [Q99502-3]
DR   GeneID; 2138; -.
DR   KEGG; hsa:2138; -.
DR   UCSC; uc003xyr.6; human. [Q99502-1]
DR   CTD; 2138; -.
DR   DisGeNET; 2138; -.
DR   GeneCards; EYA1; -.
DR   GeneReviews; EYA1; -.
DR   HGNC; HGNC:3519; EYA1.
DR   HPA; HPA028917; -.
DR   MalaCards; EYA1; -.
DR   MIM; 113650; phenotype.
DR   MIM; 166780; phenotype.
DR   MIM; 601653; gene.
DR   MIM; 602588; phenotype.
DR   neXtProt; NX_Q99502; -.
DR   OpenTargets; ENSG00000104313; -.
DR   Orphanet; 107; BOR syndrome.
DR   Orphanet; 52429; Branchio-otic syndrome.
DR   Orphanet; 2792; Otofaciocervical syndrome.
DR   PharmGKB; PA27931; -.
DR   eggNOG; KOG3107; Eukaryota.
DR   eggNOG; ENOG410XT12; LUCA.
DR   GeneTree; ENSGT00390000008860; -.
DR   HOGENOM; HOG000293149; -.
DR   HOVERGEN; HBG002447; -.
DR   InParanoid; Q99502; -.
DR   KO; K15616; -.
DR   OMA; GQPYGIS; -.
DR   OrthoDB; EOG091G04YD; -.
DR   PhylomeDB; Q99502; -.
DR   TreeFam; TF319337; -.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   SIGNOR; Q99502; -.
DR   ChiTaRS; EYA1; human.
DR   GeneWiki; EYA1; -.
DR   GenomeRNAi; 2138; -.
DR   PRO; PR:Q99502; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000104313; -.
DR   CleanEx; HS_EYA1; -.
DR   ExpressionAtlas; Q99502; baseline and differential.
DR   Genevisible; Q99502; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0032993; C:protein-DNA complex; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:Ensembl.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0035909; P:aorta morphogenesis; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0034613; P:cellular protein localization; IEA:Ensembl.
DR   GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl.
DR   GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0000132; P:establishment of mitotic spindle orientation; IEA:Ensembl.
DR   GO; GO:0035088; P:establishment or maintenance of apical/basal cell polarity; IEA:Ensembl.
DR   GO; GO:0016576; P:histone dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0060487; P:lung epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007501; P:mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0001656; P:metanephros development; IEA:Ensembl.
DR   GO; GO:0042474; P:middle ear morphogenesis; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IBA:GO_Central.
DR   GO; GO:0048665; P:neuron fate specification; IEA:Ensembl.
DR   GO; GO:0071600; P:otic vesicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0042473; P:outer ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0007389; P:pattern specification process; IEA:Ensembl.
DR   GO; GO:0060037; P:pharyngeal system development; IEA:Ensembl.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IMP:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0072513; P:positive regulation of secondary heart field cardioblast proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0016925; P:protein sumoylation; ISS:UniProtKB.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0048752; P:semicircular canal morphogenesis; IEA:Ensembl.
DR   GO; GO:0007605; P:sensory perception of sound; TAS:ProtInc.
DR   GO; GO:0014706; P:striated muscle tissue development; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR006545; EYA_dom.
DR   InterPro; IPR028472; EYA_fam.
DR   InterPro; IPR028471; Eyes_absent_h1.
DR   PANTHER; PTHR10190; PTHR10190; 1.
DR   PANTHER; PTHR10190:SF18; PTHR10190:SF18; 1.
DR   TIGRFAMs; TIGR01658; EYA-cons_domain; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Deafness; Developmental protein;
KW   Disease mutation; DNA damage; DNA repair; Hydrolase; Magnesium;
KW   Mental retardation; Metal-binding; Nucleus; Polymorphism;
KW   Protein phosphatase; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    592       Eyes absent homolog 1.
FT                                /FTId=PRO_0000218643.
FT   ACT_SITE    328    328       Nucleophile.
FT                                {ECO:0000250|UniProtKB:O00167}.
FT   ACT_SITE    330    330       Proton donor.
FT                                {ECO:0000250|UniProtKB:O00167}.
FT   METAL       328    328       Magnesium.
FT                                {ECO:0000250|UniProtKB:O00167}.
FT   METAL       330    330       Magnesium; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:O00167}.
FT   METAL       556    556       Magnesium.
FT                                {ECO:0000250|UniProtKB:O00167}.
FT   VAR_SEQ       1     41       MEMQDLTSPHSRLSGSSESPSGPKLGNSHINSNSMTPNGTE
FT                                -> MLLFPQVA (in isoform EYA1B).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_001486.
FT   VAR_SEQ     140    144       Missing (in isoform EYA1D).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_045793.
FT   VAR_SEQ     351    380       Missing (in isoform EYA1D).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_045794.
FT   VARIANT      20     20       P -> A (in dbSNP:rs1445404).
FT                                /FTId=VAR_024439.
FT   VARIANT      41     41       E -> K (found in a patient with
FT                                congenital cataract; dbSNP:rs561111097).
FT                                {ECO:0000269|PubMed:23508780}.
FT                                /FTId=VAR_070033.
FT   VARIANT      95     95       P -> S (in BOR1).
FT                                {ECO:0000269|PubMed:21280147}.
FT                                /FTId=VAR_064942.
FT   VARIANT     140    140       G -> S (in BOR1).
FT                                {ECO:0000269|PubMed:21280147}.
FT                                /FTId=VAR_064943.
FT   VARIANT     242    242       S -> G (in BOS1; dbSNP:rs191838840).
FT                                {ECO:0000269|PubMed:12701758}.
FT                                /FTId=VAR_044452.
FT   VARIANT     363    363       E -> K (in ASA; dbSNP:rs121909198).
FT                                {ECO:0000269|PubMed:10655545}.
FT                                /FTId=VAR_016864.
FT   VARIANT     363    363       E -> V (in BOR1).
FT                                {ECO:0000269|PubMed:21280147}.
FT                                /FTId=VAR_064944.
FT   VARIANT     426    426       G -> S (in BOR1; with cataract;
FT                                dbSNP:rs121909199).
FT                                {ECO:0000269|PubMed:10655545}.
FT                                /FTId=VAR_016865.
FT   VARIANT     429    429       D -> G (in BOR1).
FT                                {ECO:0000269|PubMed:11558900}.
FT                                /FTId=VAR_016866.
FT   VARIANT     440    440       R -> Q (in BOR1; dbSNP:rs121909196).
FT                                {ECO:0000269|PubMed:10464653,
FT                                ECO:0000269|PubMed:21280147}.
FT                                /FTId=VAR_016867.
FT   VARIANT     487    487       S -> P (in BOR1; dbSNP:rs121909200).
FT                                {ECO:0000269|PubMed:9361030}.
FT                                /FTId=VAR_005203.
FT   VARIANT     505    505       L -> R (in BOR1; dbSNP:rs121909201).
FT                                {ECO:0000269|PubMed:9361030}.
FT                                /FTId=VAR_005204.
FT   VARIANT     514    514       L -> P (in BOR1; dbSNP:rs112340154).
FT                                {ECO:0000269|PubMed:21280147}.
FT                                /FTId=VAR_064945.
FT   VARIANT     527    527       Y -> C (in BOR1).
FT                                {ECO:0000269|PubMed:21280147}.
FT                                /FTId=VAR_064946.
FT   VARIANT     547    547       R -> G (in ASA; with cataract;
FT                                dbSNP:rs121909197).
FT                                {ECO:0000269|PubMed:10655545}.
FT                                /FTId=VAR_016868.
FT   VARIANT     569    569       M -> T (in BOR1).
FT                                {ECO:0000269|PubMed:21280147}.
FT                                /FTId=VAR_064947.
FT   VARIANT     583    583       L -> P (in BOR1; dbSNP:rs397517920).
FT                                {ECO:0000269|PubMed:10991693}.
FT                                /FTId=VAR_016869.
FT   MUTAGEN     328    328       D->A: Loss of tyrosine phosphatase
FT                                activity toward H2AX.
FT                                {ECO:0000269|PubMed:19234442}.
FT   CONFLICT     33     33       N -> D (in Ref. 3; AAL73437).
FT                                {ECO:0000305}.
SQ   SEQUENCE   592 AA;  64593 MW;  D62365F81EB692E2 CRC64;
     MEMQDLTSPH SRLSGSSESP SGPKLGNSHI NSNSMTPNGT EVKTEPMSSS ETASTTADGS
     LNNFSGSAIG SSSFSPRPTH QFSPPQIYPS NRPYPHILPT PSSQTMAAYG QTQFTTGMQQ
     ATAYATYPQP GQPYGISSYG ALWAGIKTEG GLSQSQSPGQ TGFLSYGTSF STPQPGQAPY
     SYQMQGSSFT TSSGIYTGNN SLTNSSGFNS SQQDYPSYPS FGQGQYAQYY NSSPYPAHYM
     TSSNTSPTTP STNATYQLQE PPSGITSQAV TDPTAEYSTI HSPSTPIKDS DSDRLRRGSD
     GKSRGRGRRN NNPSPPPDSD LERVFIWDLD ETIIVFHSLL TGSYANRYGR DPPTSVSLGL
     RMEEMIFNLA DTHLFFNDLE ECDQVHIDDV SSDDNGQDLS TYNFGTDGFP AAATSANLCL
     ATGVRGGVDW MRKLAFRYRR VKEIYNTYKN NVGGLLGPAK REAWLQLRAE IEALTDSWLT
     LALKALSLIH SRTNCVNILV TTTQLIPALA KVLLYGLGIV FPIENIYSAT KIGKESCFER
     IIQRFGRKVV YVVIGDGVEE EQGAKKHAMP FWRISSHSDL MALHHALELE YL
//
